- Price
- $17.99
- Day
- -5.02%
- Mkt Cap
- $1.71B
- 52W Range
- $5.82 – $21.39
- Volume
- 2.24M
- Beta
- 2.01
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
FTRE, ASML and KLAC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2026.
Read full article
Fortrea Holdings Inc. (FTRE) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Read full article
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read full article
Fortrea Holdings Inc. (FTRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read full article
Fortrea Holdings Inc. (FTRE) Q2 2026 Earnings Call Transcript
Read full article
Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance
Read full article
Fortrea NASDAQ: FTRE reported second-quarter 2026 revenue of $678.2 million and adjusted EBITDA of $58.7 million, while raising its full-year revenue and adjusted EBITDA outlook. Management said results reflected stronger clinical pharmacology performance, cost-savings initiatives and improving commercial activity, particularly among biotechnology clients.
Read full article
Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.19 per share a year ago.
Read full article
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Fortrea Holdings Inc. (Nasdaq: FTRE) (“Fortrea”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/fortrea-holdings/ Recently a securities fraud complaint was filed against Fortrea on behalf of certain investors who purchased shares of the company's stock between July 5, 2023 and February 28, 2025 (the “Wrongdoing Period”). Accor.
Read full article